» Articles » PMID: 38755147

Serological Evidence of Zoonotic Filovirus Exposure Among Bushmeat Hunters in Guinea

Abstract

Human Ebola virus (EBOV) outbreaks caused by persistent EBOV infection raises questions on the role of zoonotic spillover in filovirus epidemiology. To characterise filovirus zoonotic exposure, we collected cross-sectional serum samples from bushmeat hunters (n = 498) in Macenta Prefecture Guinea, adjacent to the index site of the 2013 EBOV-Makona spillover event. We identified distinct immune signatures (20/498, 4.0%) to multiple EBOV antigens (GP, NP, VP40) using stepwise ELISA and Western blot analysis and, live EBOV neutralisation (5/20; 25%). Using comparative serological data from PCR-confirmed survivors of the 2013-2016 EBOV outbreak, we demonstrated that most signatures (15/20) were not plausibly explained by prior EBOV-Makona exposure. Subsequent data-driven modelling of EBOV immunological outcomes to remote-sensing environmental data also revealed consistent associations with intact closed canopy forest. Together our findings suggest exposure to other closely related filoviruses prior to the 2013-2016 West Africa epidemic and highlight future surveillance priorities.

Citing Articles

Dynamics of natural selection preceding human viral epidemics and pandemics.

Havens J, Kosakovsky Pond S, Zehr J, Pekar J, Parker E, Worobey M bioRxiv. 2025; .

PMID: 40060453 PMC: 11888428. DOI: 10.1101/2025.02.26.640439.


rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).

Watson C, Gsell P, Hall Y, Camacho A, Riveros X, Enwere G BMC Med. 2024; 22(1):523.

PMID: 39511527 PMC: 11545826. DOI: 10.1186/s12916-024-03726-z.


High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.

Ramassamy J, Ayouba A, Thaurignac G, Bilounga Ndongo C, Nnuka P, Betsem E J Infect Dis. 2024; 230(5):e1067-e1076.

PMID: 39126336 PMC: 11565877. DOI: 10.1093/infdis/jiae399.

References
1.
Kuhn J, Bavari S . Asymptomatic Ebola virus infections-myth or reality?. Lancet Infect Dis. 2017; 17(6):570-571. DOI: 10.1016/S1473-3099(17)30110-X. View

2.
Natesan M, Jensen S, Keasey S, Kamata T, Kuehne A, Stonier S . Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Clin Vaccine Immunol. 2016; 23(8):717-24. PMC: 4979172. DOI: 10.1128/CVI.00107-16. View

3.
Dowall S, Callan J, Zeltina A, Al-Abdulla I, Strecker T, Fehling S . Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection. J Infect Dis. 2015; 213(7):1124-33. PMC: 4779302. DOI: 10.1093/infdis/jiv565. View

4.
Hashiguchi T, Fusco M, Bornholdt Z, Lee J, Flyak A, Matsuoka R . Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell. 2015; 160(5):904-912. PMC: 4344967. DOI: 10.1016/j.cell.2015.01.041. View

5.
Hoff N, Mukadi P, Doshi R, Bramble M, Lu K, Gadoth A . Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo. J Infect Dis. 2018; 219(4):517-525. PMC: 6350949. DOI: 10.1093/infdis/jiy499. View